['atherosclerosis', 'cardiovascular disease']
['medi6012 40 mg', 'placebo', 'medi6012 120 mg', 'medi6012 300 mg', 'placebo iv push', 'medi6012 iv push']

        Inclusion Criteria:

          -  Non-childbearing potential

          -  Diagnosis of stable atherosclerotic CVD

          -  Currently receiving a stable dose of Statin

        Exclusion Criteria:

          -  Unstable cardiovascular condition within 3 months of screening

          -  Elective arterial revascularization with in the past month

          -  Any planned arterial revascularization

          -  Body mass index <18 or >45

          -  Clinically significant ECG that may interfere with the interpretation of serial ECG
             and QT interval changes at screening

          -  Chronic kidney disease defined by estimated glomerular filtration rate of less than 30
             mL/mim/1.73m2

          -  Triglycerides greater than 500 mg/dL, LDL-C greater than 160 mg/dL, or HDL-C greater
             than 60 for males, or 65 for females

          -  Clinically significant vital sign abnormalities

          -  Genetic disorder of cholesterol metabolism

          -  History of overt liver disease

          -  Poorly controlled endocrine disorder (Diabetes or Thyroid disorder)

          -  Current or recent use of systemic corticosteroids

          -  Recent or ongoing infection or febrile illness

          -  History of active malignancy within 5 years

          -  History of alcohol or recreational substance abuse in the past 6 months

          -  Concurrent enrollment in another clinical study of any investigational drug therapy or
             use of any biologicals within 6 months prior to screening or within 5 half-lives of an
             investigational agent or biologic, whichever is longer.
      